Evidence map›Paper›PMID 40768060›Full record

ArticleImmunologic research2025

The role of CD40L-expressing CXCR5

Fatih Akboga, Fehmi Hindilerden, Ipek Yonal Hindilerden, Emine Gulturk, Gunnur Deniz, Metin Yusuf Gelmez

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fatih AkbogaDepartment of Immunology, Istanbul University, Institute of Health Sciences, Istanbul, Türkiye.ORCID http://orcid.org/0000-0002-0202-3244
Fehmi HindilerdenDepartment of Internal Medicine Divison of Hematology, University of Health Sciences Hamidiye School of Medicine, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Türkiye.ORCID http://orcid.org/0000-0002-6297-9555
Ipek Yonal HindilerdenIstanbul Medical Faculty, Division of Internal Medicine, Department of Hematology, Istanbul University, Istanbul, Türkiye.ORCID http://orcid.org/0000-0003-1353-2367
Emine GulturkDepartment of Internal Medicine Divison of Hematology, University of Health Sciences Hamidiye School of Medicine, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Türkiye.ORCID http://orcid.org/0000-0003-2836-6162
Gunnur DenizDepartment of Immunology, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Vakıf Gureba Cad, 34393, Istanbul, Türkiye.ORCID http://orcid.org/0000-0002-0721-6213
Metin Yusuf GelmezDepartment of Immunology, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Vakıf Gureba Cad, 34393, Istanbul, Türkiye. yusufmetin@istanbul.edu.tr.ORCID http://orcid.org/0000-0002-5279-0855

Funding

Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi 38452Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 122S204
6 · The paper itself

Abstract

A newly identified cell subset within CD8

Indexed as

CD40 LigandCD8-Positive T-LymphocytesLeukemia, Lymphocytic, Chronic, B-CellReceptors, CXCR5T-Lymphocytes, CytotoxicAdultAgedAged, 80 and overCytokinesFemaleHumansMaleMiddle AgedCD40 LigandCXCR5 protein, humanCytokinesReceptors, CXCR5CD40LChronic lymphocytic leukemia,CLLFollicular cytotoxic CD8+ T cell,TFC

Identifiers

PMID40768060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.